Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Nektar Therapeutics (NKTR) and December 31 Lead Plaintiff Deadline
NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, reminds investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and other defendants, related to alleged violations of federal securities laws. If you purchased Nektar securities between November 11, 2017 and October 2, 2018, you are encouraged to contact a Scott+Scott attorney at (844) 818-6980 for more information. The lead plaintiff deadline is December 31, 2018.
Nektar is a biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. NKTR-214 is the Company's lead immune-oncology candidate, designed to stimulate a patient's own immune system to fight cancer.
According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) prior studies which attempted to pegylate (add polyethylene glycol molecules) IL-2 failed; (2) NKTR-214's extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less effective than IL-2 alone; and (4) the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results.
On October 1, 2018, Plainview LLC ("Plainview") published a report entitled "NKTR-214: Pegging the Value at Zero." The Plainview report asserted that the core concept of Nektar's plan to develop NKTR-214 into "a new universal cancer treatment" "has never worked in practice," and further asserted that Nektar's decision to only disclose certain trial results represented "an unprecedented level of data opacity."
Following publication of the Plainview report, Nektar's stock price fell $5.63 per share, or 9.24%, over the next two trading days, closing at $55.33 per share on October 2, 2018.
What You Can Do
If you purchased Nektar securities between November 11, 2017 and October 2, 2018, inclusive, or if you have questions about this notice or your legal rights, please contact attorney Rhiana Swartz at (844) 818-6980, or at rswartz@scott-scott.com.
About Scott+Scott Attorneys at Law LLP
Scott+Scott has significant experience in prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Connecticut, California, and Ohio.
Attorney Advertising
CONTACT:
Rhiana Swartz
Scott+Scott Attorneys at Law LLP
230 Park Ave, 17(th) Fl, NY, NY 10169
(844) 818-6980
rswartz@scott-scott.com
SOURCE Scott+Scott Attorneys at Law LLP
